仙琚製藥(002332.SZ):放棄索元生物增資優先認購權
格隆匯 6 月 23日丨仙琚製藥(002332.SZ)公佈,索元生物醫藥(杭州)有限公司(“索元生物”)系公司的參股公司,公司持有其14.8010%的股權。公司於2020年4月收到索元生物關於擬增資事項的通知,並於2020年4月23日召開的第七屆董事會第二次會議已審議放棄索元生物增資優先認購權事項。
近日,公司收到索元生物通知,根據增資事項進展,增資方案擬進行調整:擬增資金額由5億元人民幣調整為5.9億元人民幣,增資對象由11家調整為17家。調整後的擬增資方案為:
索元生物註冊資本將由目前的6688.7418萬元人民幣增加到8844.4252萬元人民幣,增資價格為27.3695元/股。從次增資由索元生物原股東江蘇疌泉仙瞳生物醫療創業投資合夥企業(有限合夥)並同時吸納新投資方中金啟德(廈門)創新生物醫療股權投資基金合夥企業(有限合夥)等共17家企業參與,參與增資的所有認購方以現金出資合計5.9億元人民幣,認購索元生物的新增註冊資本。
此次增資完成後,公司持有索元生物的股權比例由原來的14.8010%降至11.1935%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.